China Emerges as a New Frontier for Global Medical Tourism

The influx of foreign patients is anchored by a combination of policy shifts and localized access to cutting-edge treatments. China’s 240-hour visa-free transit policy for 57 countries now serves as a key logistical gateway, while the domestic approval of novel therapies—such as the world’s first CAR-T treatment for solid tumors—creates a unique competitive advantage. In the first half of 2026 alone, Jiahui Health reported a near doubling of overseas inquiries compared to the previous year.

Concrete examples underscore the shift in patient behavior. A New Zealand patient recently traveled to Shanghai to become the first international recipient of China’s newly approved CAR-T therapy, while a U.S. patient sought out ivonescimab, a bispecific antibody currently exclusive to the Chinese market. These cases reflect a broader trend of patients crossing borders to access regional medical innovation. To sustain this momentum, Dr. Hsiang emphasized the need for standardized regulatory dialogues regarding telemedicine and cross-border health data, positioning China to potentially lead the international medical tourism sector within the next five years.